AstraZeneca and Daiichi Sankyo withdraw EU application for datopotamab deruxtecan in NSCLC after Phase III trial shows no ...

Viatris faces US FDA regulatory action on its Indore, India facility, with a warning letter and import alert restricting 11 ...

US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055 ...

The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza ...

The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...

USA-based immunology company RAPT Therapeutics has entered into an exclusive license agreement with Shanghai Jemincare ...

USA-based clinical-stage biopharma Traws Pharma saw its shares leap more than 150% to $12.57 as it announced progress in the ...

Cytokinetics (Nasdaq: CYTK) has sold Sanofi (Euronext: SAN) exclusive rights to develop and commercialize aficamten in China.

Poxel is a biopharmaceutical company developing drugs for metabolic diseases, with a focus on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono. Poxel is focsed on ...

Shionogi to acquire full ownership of its joint ventures with Ping An subsidiaries, dissolving partnerships to refocus on ...

XBiotech halts rheumatology program after Phase II trial failure for rheumatoid arthritis, citing data irregularities and ...

US pharma major Eli Lilly today announced the US Food and Drug Administration (FDA) approved Zepbound its (tirzepatide) as ...